ProNAi appoints Christian Hassig as SVP of research
Dr. Hassig will lead ProNAi's research activities from discovery research through to early candidate development. Dr. Hassig has a strong record of accomplishments in both discovery research and preclinical development across multiple therapeutic areas and has pioneered lead discovery projects against innovative targets in oncology, from target discovery through to IND.
At the Sanford Burnham Prebys Medical Discovery Institute, Dr. Hassig drove the advancement of the institute's discovery pipeline across oncology as well as several other therapeutic areas.
During his academic career, he conducted seminal work in the area of chromatin regulation, including the purification, cloning and characterization of several members of the histone deacetylase (HDAC) family of enzymes, targets which have been the focus of several advanced oncology drug development programs.
Dr. Hassig maintains an adjunct faculty appointment at The Scripps Research Institute in La Jolla.
He was formerly the Vice President of Drug Discovery at the Sanford Burnham Prebys Medical Discovery Institute, having previously served as its Director of Drug Discovery from 2010 to 2015.
Prior to this, Dr. Hassig served as the Department Head of Biology at Kalypsys, Inc., a privately owned biopharmaceutical company specializing in small molecule drug discovery and development, and held multiple roles within its Biology and Lead Discovery departments.
Dr. Hassig holds a B.A. in Chemistry/Biochemistry from the University of California, San Diego, and a Ph.D. from Harvard University. He completed a Postdoctoral Fellowship at the University of California, Berkeley. ■
LATEST MOVES FROM British Columbia
- Arak Resources appoints Jonathan Hykawy as director
- Arbutus Biopharma appoints Daniel Burgess as director
- International Lithium Corp. names CFO, announces further additions
- Asiamet Resources appoints Peter John Bird as CEO
- International Lithium Corp. names Maurice Brooks to board
More inside POST